We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Memphis to House New Biological Reagents R&D and Manufacturing Center

By LabMedica International staff writers
Posted on 23 Aug 2010
A major supplier of biological reagents to the biotech and life science community has announced an ambitious plan for additional investments into facilities, equipment, and infrastructure to support research and development (R&D) and contract manufacturing activities.

Meridian Life Science, Inc. More...
(Cincinnati, OH, USA) cited increased demand for contract R&D and biological reagent manufacturing as the motivating factors behind the renovation and expansion scheme, which follows the 2009 investment that resulted in an additional cleanroom biomanufacturing suite, a sterility suite, and a pilot production laboratory.

The new facility will be located in Memphis, TN, USA, where it will consolidate all current R&D laboratories in a centralized R&D center. Other areas of the facility will be available for construction of up to five contract manufacturing, cell culture, and purification laboratories designed to support increased demand for contract manufacturing of monoclonal antibodies, viral antigens, and recombinant proteins.

The R&D center and the contract manufacturing laboratories will be equipped with state of the art systems for cell culture and protein purification. Also included in the expansion plan is the construction of a molecular biology laboratory with RT-PCR capabilities and an expanded quality control laboratory for testing incoming and outgoing materials.

Dr. Lourdes Weltzien, general manager of the Meridian Life Science Memphis Facility, said, "This recent round of expansion is necessary to provide the level and quality of contract manufacturing support our customers expect and require for their custom and critical biological reagents. We are excited and committed to increasing our capacity to service our customers, who can benefit from our core competence in cell culture, protein production, and purification. This recent expansion reaffirms our commitment as a leader in contract R&D and biologics manufacturing."

Related Links:
Meridian Life Science, Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.